RECHERCHE :   Cancers de la peau
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
AMGEN 20120139: A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Tous les types de tumeurs
registre
CHUV
BMS CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Mélanome, cancer de la vessie
I
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CHUV-DO-ATATIL-2016 - Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma
Mélanome
I
CHUV
CMCS110Z2102: A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies
Tumeurs malignes avancées: pancréas, sein triple négatif, endomètre, mélanome
II
HUG
EORTC 1208 (Minitub): Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Positive Mélanome positif en ganglion sentinelle (SN)
registre
CHUV
MK3475-716: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
Mélanome de Stade IIB ou IIC réséqué (Resected Highrisk Stage II Melanoma)
III
CHUV, HUG
PEMSYS: An interventional phase II study to a nalyze the modulation of the tumor microenvironment by MK-3475 (pembrolizumab,) using a systems biology approach
Mélanome cutané avancé ou métastatique
II
CHUV